Neurobiology of Schizophrenia

Neuron

Volumn 52, Issue 1, 2006, Pages 139-153

  Ross, Christopher A ^a   Margolis, Russell L ^a   Reading, Sarah A J ^a   Pletnikov, Mikhail ^a   Coyle, Joseph T ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ATYPICAL ANTIPSYCHOTIC AGENT; CATHECOL O METHYLTRANSFERASE; CHLORPROMAZINE; CLOZAPINE; CYCLOSERINE; DEXTRO ALANINE; DEXTRO AMINO ACID OXIDASE ACTIVATOR PROTEIN; DEXTRO SERINE; DYSBINDIN; GENE PRODUCT; GLYCINE; HALOPERIDOL; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR AGONIST; NEU DIFFERENTIATION FACTOR; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PROTEIN DISC1; SARCOSINE; UNCLASSIFIED DRUG;

BRAIN DEVELOPMENT; CELL ACTIVITY; CHROMOSOME 22Q; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; DECISION MAKING; DEGENERATIVE DISEASE; DELUSION; DEVELOPMENTAL DISORDER; DISEASE ASSOCIATION; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DYSKINESIA; DYSTONIA; EMOTION; ENVIRONMENTAL FACTOR; EVIDENCE BASED MEDICINE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE DISRUPTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC RISK; GENETIC VARIABILITY; GENETICS; HALLUCINATION; HUMAN; HYPERLIPIDEMIA; MENTAL DISEASE; MOLECULAR DYNAMICS; NERVE CELL PLASTICITY; NEUROBIOLOGY; NEUROIMAGING; NEUROPATHOLOGY; NEUROPSYCHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; PATHOPHYSIOLOGY; PERCEPTION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; RIGIDITY; SCHIZOPHRENIA; SIDE EFFECT; THOUGHT DISORDER; TREMOR;

ANIMALS; CHROMOSOMES, HUMAN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LINKAGE (GENETICS); NEUROBIOLOGY; SCHIZOPHRENIA;

EID: 33749041047     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuron.2006.09.015     Document Type: Review

References (122)

1. Abdolmaleky H.M., Cheng K.H., Russo A., Smith C.L., Faraone S.V., Wilcox M., Shafa R., Glatt S.J., Nguyen G., Ponte J.F., et al. Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: a preliminary report. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 134 (2005) 60-66
2. Akbarian S., Kim J.J., Potkin S.G., Hetrick W.P., Bunney Jr. W.E., and Jones E.G. Maldistribution of interstitial neurons in prefrontal white matter of the brains of schizophrenic patients. Arch. Gen. Psychiatry 53 (1996) 425-436
3. Antonova E., Sharma T., Morris R., and Kumari V. The relationship between brain structure and neurocognition in schizophrenia: a selective review. Schizophr. Res. 70 (2004) 117-145
4. Arnold S.E., Ruscheinsky D.D., and Han L.Y. Further evidence of abnormal cytoarchitecture of the entorhinal cortex in schizophrenia using spatial point pattern analyses. Biol. Psychiatry 42 (1997) 639-647
5. Arnold S.E., Trojanowski J.Q., Gur R.E., Blackwell P., Han L.Y., and Choi C. Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia. Arch. Gen. Psychiatry 55 (1998) 225-232
6. Arnold S.E., Talbot K., and Hahn C.G. Neurodevelopment, neuroplasticity, and new genes for schizophrenia. Prog. Brain Res. 147 (2005) 319-345
7. Austin C.P., Ma L., Ky B., Morris J.A., and Shughrue P.J. DISC1 (Disrupted in Schizophrenia-1) is expressed in limbic regions of the primate brain. Neuroreport 14 (2003) 951-954
8. Benson M.A., Newey S.E., Martin-Rendon E., Hawkes R., and Blake D.J. Dysbindin, a novel coiled-coil-containing protein that interacts with the dystrobrevins in muscle and brain. J. Biol. Chem. 276 (2001) 24232-24241
9. Blackwood D.H., Fordyce A., Walker M.T., St Clair D.M., Porteous D.J., and Muir W.J. Schizophrenia and affective disorders-cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. Am. J. Hum. Genet. 69 (2001) 428-433
10. Bowie C.R., and Harvey P.D. Cognition in schizophrenia: impairments, determinants, and functional importance. Psychiatr. Clin. North. Am. 28 (2005) 613-633 626
11. Bramon E., Dempster E., Frangou S., McDonald C., Schoenberg P., MacCabe J.H., Walshe M., Sham P., Collier D., and Murray R.M. Is there an association between the COMT gene and P300 endophenotypes?. Eur. Psychiatry 21 (2006) 70-73
12. Brandon N.J., Handford E.J., Schurov I., Rain J.C., Pelling M., Duran-Jimeniz B., Camargo L.M., Oliver K.R., Beher D., Shearman M.S., and Whiting P.J. Disrupted in Schizophrenia 1 and Nudel form a neurodevelopmentally regulated protein complex: implications for schizophrenia and other major neurological disorders. Mol. Cell. Neurosci. 25 (2004) 42-55
13. Bray N.J., Preece A., Williams N.M., Moskvina V., Buckland P.R., Owen M.J., and O'Donovan M.C. Haplotypes at the dystrobrevin binding protein 1 (DTNBP1) gene locus mediate risk for schizophrenia through reduced DTNBP1 expression. Hum. Mol. Genet. 14 (2005) 1947-1954
14. Brown A.S., and Susser E.S. In utero infection and adult schizophrenia. Ment. Retard. Dev. Disabil. Res. Rev. 8 (2002) 51-57
15. Burdick K.E., Lencz T., Funke B., Finn C.T., Szeszko P.R., Kane J.M., Kucherlapati R., and Malhotra A.K. Genetic variation in DTNBP1 influences general cognitive ability. Hum. Mol. Genet. 15 (2006) 1563-1568
16. Callicott J.H., Straub R.E., Pezawas L., Egan M.F., Mattay V.S., Hariri A.R., Verchinski B.A., Meyer-Lindenberg A., Balkissoon R., Kolachana B., et al. Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Proc. Natl. Acad. Sci. USA 102 (2005) 8627-8632
17. Cannon M., Jones P.B., and Murray R.M. Obstetric complications and schizophrenia: historical and meta-analytic review. Am. J. Psychiatry 159 (2002) 1080-1092
18. Cannon T.D. The inheritance of intermediate phenotypes for schizophrenia. Curr. Opin. Psychiatry 18 (2005) 135-140
19. Cannon T.D., Hennah W., van Erp T.G., Thompson P.M., Lonnqvist J., Huttunen M., Gasperoni T., Tuulio-Henriksson A., Pirkola T., Toga A.W., et al. Association of DISC1/TRAX haplotypes with schizophrenia, reduced prefrontal gray matter, and impaired short- and long-term memory. Arch. Gen. Psychiatry 62 (2005) 1205-1213
20. Caspi A., and Moffitt T.E. Gene-environment interactions in psychiatry: joining forces with neuroscience. Nat. Rev. Neurosci. 7 (2006) 583-590
21. CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 (2005) 1209-1223
22. Chen J., Lipska B.K., and Weinberger D.R. Genetic mouse models of schizophrenia: from hypothesis-based to susceptibility gene-based models. Biol. Psychiatry 59 (2006) 1180-1188
23. Coyle J.T. Glutamate and schizophrenia: Beyond the dopamine hypothesis. Cell. Mol. Neurobiol. (2006) 10.1007/s10571-006-9062-8 in press. Published online June 14, 2006
24. Craddock N., O'Donovan M.C., and Owen M.J. The genetics of schizophrenia and bipolar disorder: dissecting psychosis. J. Med. Genet. 42 (2005) 193-204
25. Craddock N., Owen M.J., and O'Donovan M.C. The catechol-O-methyl transferase (COMT) gene as a candidate for psychiatric phenotypes: evidence and lessons. Mol. Psychiatry 11 (2006) 446-458
26. D'Arcangelo G. Reelin mouse mutants as models of cortical development disorders. Epilepsy Behav. 8 (2006) 81-90
27. DeRosse P., Funke B., Burdick K.E., Lencz T., Ekholm J.M., Kane J.M., Kucherlapati R., and Malhotra A.K. Dysbindin genotype and negative symptoms in schizophrenia. Am. J. Psychiatry 163 (2006) 532-534
28. Detera-Wadleigh S.D., and McMahon F.J. G72/G30 in schizophrenia and bipolar disorder: review and meta-analysis. Biol. Psychiatry 60 (2006) 106-114
29. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzanti C.M., Straub R.E., Goldman D., and Weinberger D.R. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl. Acad. Sci. USA 98 (2001) 6917-6922
30. Ekelund J., Hovatta I., Parker A., Paunio T., Varilo T., Martin R., Suhonen J., Ellonen P., Chan G., Sinsheimer J.S., et al. Chromosome 1 loci in Finnish schizophrenia families. Hum. Mol. Genet. 10 (2001) 1611-1617
31. Erwin R.J., Turetsky B.I., Moberg P., Gur R.C., and Gur R.E. P50 abnormalities in schizophrenia: relationship to clinical and neuropsychological indices of attention. Schizophr. Res. 33 (1998) 157-167
32. Ettinger U., Picchioni M., Hall M.H., Schulze K., Toulopoulou T., Landau S., Crawford T.J., and Murray R.M. Antisaccade performance in monozygotic twins discordant for schizophrenia: the Maudsley twin study. Am. J. Psychiatry 163 (2006) 543-545
33. Fallgatter A.J., Herrmann M.J., Hohoff C., Ehlis A.C., Jarczok T.A., Freitag C.M., and Deckert J. DTNBP1 (Dysbindin) gene variants modulate prefrontal brain function in healthy individuals. Neuropsychopharmacology 31 (2006) 2002-2010 10.1038/sj.npp.1301003 Published online January 11, 2006
34. Falls D.L. Neuregulins: functions, forms, and signaling strategies. Exp. Cell Res. 284 (2003) 14-30
35. Fanous A.H., van den Oord E.J., Riley B.P., Aggen S.H., Neale M.C., O'Neill F.A., Walsh D., and Kendler K.S. Relationship between a high-risk haplotype in the DTNBP1 (dysbindin) gene and clinical features of schizophrenia. Am. J. Psychiatry 162 (2005) 1824-1832
36. Freedman R. Schizophrenia. N. Engl. J. Med. 349 (2003) 1738-1749
37. Gilmore J.H., and Jarskog L.F. Exposure to infection and brain development: cytokines in the pathogenesis of schizophrenia. Schizophr. Res. 24 (1997) 365-367
38. Gold J.M. Cognitive deficits as treatment targets in schizophrenia. Schizophr. Res. 72 (2004) 21-28
39. Goldman-Rakic P.S. The physiological approach: functional architecture of working memory and disordered cognition in schizophrenia. Biol. Psychiatry 46 (1999) 650-661
40. Gornick M.C., Addington A.M., Sporn A., Gogtay N., Greenstein D., Lenane M., Gochman P., Ordonez A., Balkissoon R., Vakkalanka R., et al. Dysbindin (DTNBP1, 6p22.3) is associated with childhood-onset psychosis and endophenotypes measured by the Premorbid Adjustment Scale (PAS). J. Autism Dev. Disord. 35 (2005) 831-838
41. Gothelf D., Eliez S., Thompson T., Hinard C., Penniman L., Feinstein C., Kwon H., Jin S., Jo B., Antonarakis S.E., et al. COMT genotype predicts longitudinal cognitive decline and psychosis in 22q11.2 deletion syndrome. Nat. Neurosci. 8 (2005) 1500-1502
42. Gottesman I.I., and Gould T.D. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 160 (2003) 636-645
43. Green E.K., Norton N., Peirce T., Grozeva D., Kirov G., Owen M.J., O'Donovan M.C., and Craddock N. Evidence that a DISC1 frame-shift deletion associated with psychosis in a single family may not be a pathogenic mutation. Mol. Psychiatry 11 (2006) 798-799
44. Hahn C.G., Wang H.Y., Cho D.S., Talbot K., Gur R.E., Berrettini W.H., Bakshi K., Kamins J., Borgmann-Winter K.E., Siegel S.J., et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA> receptor hypofunction in schizophrenia. Nat. Med. 12 (2006) 824-828
45. Hamshere M.L., Bennett P., Williams N., Segurado R., Cardno A., Norton N., Lambert D., Williams H., Kirov G., Corvin A., et al. Genomewide linkage scan in schizoaffective disorder: significant evidence for linkage at 1q42 close to DISC1, and suggestive evidence at 22q11 and 19p13. Arch. Gen. Psychiatry 62 (2005) 1081-1088
46. Harrison P.J., and Law A.J. Neuregulin 1 and Schizophrenia: Genetics, Gene Expression, and Neurobiology. Biol. Psychiatry. 60 (2006) 132-140 10.1016/j.biopsych.2005.11.002 Published online January 25, 2006
47. Harrison P.J., and Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry 10 (2005) 40-68
48. Harvey P.D., Green M.F., McGurk S.R., and Meltzer H.Y. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology (Berl.) 169 (2003) 404-411
49. Hatten M.E. New directions in neuronal migration. Science 297 (2002) 1660-1663
50. Hennah W., Thomson P., Peltonen L., and Porteous D. Genes and schizophrenia: beyond schizophrenia: The role of DISC1 in major mental illness. Schizophr. Bull. 32 (2006) 409-416
51. Heresco-Levy U., Ermilov M., Shimoni J., Shapira B., Silipo G., and Javitt D.C. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am. J. Psychiatry 159 (2002) 480-482
52. Honea R., Crow T.J., Passingham D., and Mackay C.E. Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. Am. J. Psychiatry 162 (2005) 2233-2245
53. Honer W.G., Young C., and Falkai P. Synaptic pathology. In: Harrison P.J., and Roberts G.W. (Eds). The Neuropathology of Schizophrenia (2000), Oxford University Press, New York 105-136
54. Hong L.E., Mitchell B.D., Avila M.T., Adami H., McMahon R.P., and Thaker G.K. Familial aggregation of eye-tracking endophenotypes in families of schizophrenic patients. Arch. Gen. Psychiatry 63 (2006) 259-264
55. Ishizuka K., Paek M., Kamiya A., and Sawa A. A review of Disrupted-In-Schizophrenia-1 (DISC1): neurodevelopment, cognition, and mental conditions. Biol. Psychiatry 59 (2006) 1189-1197
56. Kamiya A., Kubo K., Tomoda T., Takaki M., Youn R., Ozeki Y., Sawamura N., Park U., Kudo C., Okawa M., et al. A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development. Nat. Cell Biol. 7 (2005) 1167-1178
57. Kanaan R.A., Kim J.S., Kaufmann W.E., Pearlson G.D., Barker G.J., and McGuire P.K. Diffusion tensor imaging in schizophrenia. Biol. Psychiatry 58 (2005) 921-929
58. Karayiorgou M., Morris M.A., Morrow B., Shprintzen R.J., Goldberg R., Borrow J., Gos A., Nestadt G., Wolyniec P.S., Lasseter V.K., et al. Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11. Proc. Natl. Acad. Sci. USA 92 (1995) 7612-7616
59. Kato M., and Dobyns W.B. Lissencephaly and the molecular basis of neuronal migration. Hum. Mol. Genet. 12 Spec No 1 (2003) R89-R96
60. Katsel P.L., Davis K.L., and Haroutunian V. Large-scale microarray studies of gene expression in multiple regions of the brain in schizophrenia and Alzheimer's disease. Int. Rev. Neurobiol. 63 (2005) 41-82
61. Kellendonk C., Simpson E.H., Polan H.J., Malleret G., Vronskaya S., Winiger V., Moore H., and Kandel E.R. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 49 (2006) 603-615
62. Kirkpatrick B., Buchanan R.W., Ross D.E., and Carpenter Jr. W.T. A separate disease within the syndrome of schizophrenia. Arch. Gen. Psychiatry 58 (2001) 165-171
63. Koike H., Arguello P.A., Kvajo M., Karayiorgou M., and Gogos J.A. Disc1 is mutated in the 129S6/SvEv strain and modulates working memory in mice. Proc. Natl. Acad. Sci. USA 103 (2006) 3693-3697
64. Kubicki M., Westin C.F., McCarley R.W., and Shenton M.E. The application of DTI to investigate white matter abnormalities in schizophrenia. Ann. N Y Acad. Sci. 1064 (2005) 134-148
65. Kyle U.G., and Pichard C. The Dutch Famine of 1944-1945: a pathophysiological model of long-term consequences of wasting disease. Curr. Opin. Clin. Nutr. Metab. Care 9 (2006) 388-394
66. Lane H.Y., Chang Y.C., Liu Y.C., Chiu C.C., and Tsai G.E. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch. Gen. Psychiatry 62 (2005) 1196-1204
67. Lewis D.A., and Lieberman J.A. Catching up on schizophrenia: natural history and neurobiology. Neuron 28 (2000) 325-334
68. Lewis D.A., Hashimoto T., and Volk D.W. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 6 (2005) 312-324
69. Li W., Zhang Q., Oiso N., Novak E.K., Gautam R., O'Brien E.P., Tinsley C.L., Blake D.J., Spritz R.A., Copeland N.G., et al. Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). Nat. Genet. 35 (2003) 84-89
70. Lipska B.K., Peters T., Hyde T.M., Halim N., Horowitz C., Mitkus S., Weickert C.S., Matsumoto M., Sawa A., Straub R.E., et al. Expression of DISC1 binding partners is reduced in schizophrenia and associated with DISC1 SNPs. Hum. Mol. Genet. 15 (2006) 1245-1258
71. Long J.M., Laporte P., Merscher S., Funke B., Saint-Jore B., Puech A., Kucherlapati R., Morrow B.E., Skoultchi A.I., and Wynshaw-Boris A. Behavior of mice with mutations in the conserved region deleted in velocardiofacial/DiGeorge syndrome. Neurogenetics (2006) 10.1007/s10048-006-0054-0 in press. Published online August 10, 2006
72. Lymer G.K., Job D.E., William T., Moorhead J., McIntosh A.M., Owens D.G., Johnstone E.C., and Lawrie S.M. Brain-behaviour relationships in people at high genetic risk of schizophrenia. NeuroImage (2006) 10.1016/j.neuroimage.2006.06.031 in press. Published online August 18, 2006
73. Margolis R.L., Holmes S.E., Rudnicki D., O'Hearn E., Ross C.A., Pletnikova O., and Troncoso J.C. Huntington's disease-like 2. In: Wells R., and Ashizawa T. (Eds). Genetic Instabilities in Human Disease (2006), Academic Press, Amsterdam 261-273
74. McEvoy J.P., Lieberman J.A., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A., Swartz M.S., Perkins D.O., Keefe R.S., Davis C.E., et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 163 (2006) 600-610
75. Millar J.K., Christie S., and Porteous D.J. Yeast two-hybrid screens implicate DISC1 in brain development and function. Biochem. Biophys. Res. Commun. 311 (2003) 1019-1025
76. Millar J.K., Pickard B.S., Mackie S., James R., Christie S., Buchanan S.R., Malloy M.P., Chubb J.E., Huston E., Baillie G.S., et al. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science 310 (2005) 1187-1191
77. Miyoshi K., Honda A., Baba K., Taniguchi M., Oono K., Fujita T., Kuroda S., Katayama T., and Tohyama M. Disrupted-In-Schizophrenia 1, a candidate gene for schizophrenia, participates in neurite outgrowth. Mol. Psychiatry 8 (2003) 685-694
78. Miyoshi K., Asanuma M., Miyazaki I., Diaz-Corrales F.J., Katayama T., Tohyama M., and Ogawa N. DISC1 localizes to the centrosome by binding to kendrin. Biochem. Biophys. Res. Commun. 317 (2004) 1195-1199
79. Moghaddam B. Bringing order to the glutamate chaos in schizophrenia. Neuron 40 (2003) 881-884
80. Mohn A.R., Gainetdinov R.R., Caron M.G., and Koller B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98 (1999) 427-436
81. Morris J.A., Kandpal G., Ma L., and Austin C.P. DISC1 (Disrupted-In-Schizophrenia 1) is a centrosome-associated protein that interacts with MAP1A, MIPT3, ATF4/5 and NUDEL: regulation and loss of interaction with mutation. Hum. Mol. Genet. 12 (2003) 1591-1608
82. Murphy K.C., Jones L.A., and Owen M.J. High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch. Gen. Psychiatry 56 (1999) 940-945
83. Niemi L.T., Suvisaari J.M., Tuulio-Henriksson A., and Lonnqvist J.K. Childhood developmental abnormalities in schizophrenia: evidence from high-risk studies. Schizophr. Res. 60 (2003) 239-258
84. Niznikiewicz M.A., Kubicke M., and Shenton M.E. Recent structural and functional imaging findings in schizophrenia. Curr. Opin. Psych. 16 (2003) 123-147
85. Nuechterlein K.H., Barch D.M., Gold J.M., Goldberg T.E., Green M.F., and Heaton R.K. Identification of separable cognitive factors in schizophrenia. Schizophr. Res. 72 (2004) 29-39
86. Numakawa T., Yagasaki Y., Ishimoto T., Okada T., Suzuki T., Iwata N., Ozaki N., Taguchi T., Tatsumi M., Kamijima K., et al. Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum. Mol. Genet. 13 (2004) 2699-2708
87. Ogawa F., Kasai M., and Akiyama T. A functional link between Disrupted-In-Schizophrenia 1 and the eukaryotic translation initiation factor 3. Biochem. Biophys. Res. Commun. 338 (2005) 771-776
88. Olson E.C., and Walsh C.A. Smooth, rough and upside-down neocortical development. Curr. Opin. Genet. Dev. 12 (2002) 320-327
89. Owen M.J., Craddock N., and O'Donovan M.C. Schizophrenia: genes at last?. Trends Genet. 21 (2005) 518-525
90. Ozeki Y., Tomoda T., Kleiderlein J., Kamiya A., Bord L., Fujii K., Okawa M., Yamada N., Hatten M.E., Snyder S.H., et al. Disrupted-in-Schizophrenia-1 (DISC-1): mutant truncation prevents binding to NudE-like (NUDEL) and inhibits neurite outgrowth. Proc. Natl. Acad. Sci. USA 100 (2003) 289-294
91. Pantelis C., Yucel M., Wood S.J., Velakoulis D., Sun D., Berger G., Stuart G.W., Yung A., Phillips L., and McGorry P.D. Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophr. Bull. 31 (2005) 672-696
92. Paterlini M., Zakharenko S.S., Lai W.S., Qin J., Zhang H., Mukai J., Westphal K.G., Olivier B., Sulzer D., Pavlidis P., et al. Transcriptional and behavioral interaction between 22q11.2 orthologs modulates schizophrenia-related phenotypes in mice. Nat. Neurosci. 8 (2005) 1586-1594
93. Patterson P.H. Maternal infection: window on neuroimmune interactions in fetal brain development and mental illness. Curr. Opin. Neurobiol. 12 (2002) 115-118
94. Pickard B.S., Malloy M.P., Porteous D.J., Blackwood D.H., and Muir W.J. Disruption of a brain transcription factor, NPAS3, is associated with schizophrenia and learning disability. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 136 (2005) 26-32
95. Pickard B.S., Malloy M.P., Christoforou A., Thomson P.A., Evans K.L., Morris S.W., Hampson M., Porteous D.J., Blackwood D.H., and Muir W.J. Cytogenetic and genetic evidence supports a role for the kainate-type glutamate receptor gene, GRIK4, in schizophrenia and bipolar disorder. Mol Psychiatry 11 (2006) 847-857 10.1038/sj.mp.4001867 Published online July 4, 2006
96. Pieper A.A., Wu X., Han T.W., Estill S.J., Dang Q., Wu L.C., Reece-Fincanon S., Dudley C.A., Richardson J.A., Brat D.J., and McKnight S.L. The neuronal PAS domain protein 3 transcription factor controls FGF-mediated adult hippocampal neurogenesis in mice. Proc. Natl. Acad. Sci. USA 102 (2005) 14052-14057
97. Porteous D.J., and Millar J.K. Disrupted in schizophrenia 1: building brains and memories. Trends Mol. Med. 12 (2006) 255-261
98. Porteous D.J., Thomson P., Brandon N.J., and Millar J.K. The genetics and biology of disc1-an emerging role in psychosis and cognition. Biol. Psychiatry 60 (2006) 123-131
99. Rapoport J.L., Addington A.M., Frangou S., and Psych M.R. The neurodevelopmental model of schizophrenia: update 2005. Mol. Psychiatry 10 (2005) 434-449
100. Riley B., and Kendler K.S. Molecular genetic studies of schizophrenia. Eur. J. Hum. Genet. 14 (2006) 669-680
101. Ross C.A., and Pearlson G.D. Schizophrenia, the heteromodal association neocortex and development: potential for a neurogenetic approach. Trends Neurosci. 19 (1996) 171-176
102. Ross C.A., and Poirier M.A. Opinion: What is the role of protein aggregation in neurodegeneration?. Nat. Rev. Mol. Cell Biol. 6 (2005) 891-898
103. Ross D.E., and Margolis R.L. Neurogenetics: insights into degenerative diseases and approaches to schizophrenia. Clin. Neurosci. Res. 5 (2005) 3-14
104. Sachs N.A., Sawa A., Holmes S.E., Ross C.A., DeLisi L.E., and Margolis R.L. A frameshift mutation in Disrupted in Schizophrenia 1 in an American family with schizophrenia and schizoaffective disorder. Mol. Psychiatry 10 (2005) 758-764
105. Schurov I.L., Handford E.J., Brandon N.J., and Whiting P.J. Expression of disrupted in schizophrenia 1 (DISC1) protein in the adult and developing mouse brain indicates its role in neurodevelopment. Mol. Psychiatry 9 (2004) 1100-1110
106. Selemon L.D., and Goldman-Rakic P.S. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol. Psychiatry 45 (1999) 17-25
107. Selemon L.D., Rajkowska G., and Goldman-Rakic P.S. Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch. Gen. Psychiatry 52 (1995) 805-818
108. Singleton A., Myers A., and Hardy J. The law of mass action applied to neurodegenerative disease: a hypothesis concerning the etiology and pathogenesis of complex diseases. Hum. Mol. Genet. 13 Spec No 1 (2004) R123-R126
109. Smith W.W., Pei Z., Jiang H., Moore D.J., Liang Y., West A.B., Dawson V.L., Dawson T.M., and Ross C.A. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl. Acad. Sci. USA 102 (2005) 18676-18681
110. Snitz B.E., Macdonald III A.W., and Carter C.S. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr. Bull. 32 (2006) 179-194
111. Snyder S.H. Dopamine receptor excess and mouse madness. Neuron 49 (2006) 484-485
112. St Clair D., Xu M., Wang P., Yu Y., Fang Y., Zhang F., Zheng X., Gu N., Feng G., Sham P., and He L. Rates of adult schizophrenia following prenatal exposure to the Chinese famine of 1959-1961. JAMA 294 (2005) 557-562
113. Stefansson H., Sigurdsson E., Steinthorsdottir V., Bjornsdottir S., Sigmundsson T., Ghosh S., Brynjolfsson J., Gunnarsdottir S., Ivarsson O., Chou T.T., et al. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 71 (2002) 877-892
114. Straub R.E., and Weinberger D.R. Schizophrenia genes - famine to feast. Biol. Psychiatry 60 (2006) 81-83
115. Straub R.E., Jiang Y., MacLean C.J., Ma Y., Webb B.T., Myakishev M.V., Harris-Kerr C., Wormley B., Sadek H., Kadambi B., et al. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am. J. Hum. Genet. 71 (2002) 337-348
116. Talbot K., Eidem W.L., Tinsley C.L., Benson M.A., Thompson E.W., Smith R.J., Hahn C.G., Siegel S.J., Trojanowski J.Q., Gur R.E., et al. Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J. Clin. Invest. 113 (2004) 1353-1363
117. Thomson P.A., Wray N.R., Millar J.K., Evans K.L., Hellard S.L., Condie A., Muir W.J., Blackwood D.H., and Porteous D.J. Association between the TRAX/DISC locus and both bipolar disorder and schizophrenia in the Scottish population. Mol. Psychiatry 10 (2005) 616 657-668
118. Tsai L.H., and Gleeson J.G. Nucleokinesis in neuronal migration. Neuron 46 (2005) 383-388
119. Tunbridge E.M., Harrison P.J., and Weinberger D.R. Catechol-o-methyltransferase, cognition, and psychosis: Val(158)Met and beyond. Biol. Psychiatry 60 (2006) 141-151
120. Turner J.A., Smyth P., Macciardi F., Fallon J.H., Kennedy J.L., and Potkin S.G. Imaging phenotypes and genotypes in schizophrenia. Neuroinformatics 4 (2006) 21-49
121. Verdoux H. Perinatal risk factors for schizophrenia: how specific are they?. Curr. Psychiatry Rep. 6 (2004) 162-167
122. Yolken R.H., Karlsson H., Yee F., Johnston-Wilson N.L., and Torrey E.F. Endogenous retroviruses and schizophrenia. Brain Res. Brain Res. Rev. 31 (2000) 193-199